ORAGENICS INC (OGEN): Nasdaq/NYSE listing notice — Oragenics receives NYSE American noncompliance notice; equity $3.2M below $4M/$6M thresholds

ORAGENICS INC

NYSE American notified Oragenics it fails continued listing standards due to stockholders' equity of $3.2M as of Dec 31, 2023.
Company must submit a compliance plan by May 18, 2024 to address Sections 1003(a)(ii) and 1003(a)(iii) deficiencies.
Company has until October 18, 2025 to regain compliance; stock trades as OGEN.BC during this period.
If plan is not accepted or compliance not achieved, Oragenics faces potential delisting from NYSE American.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ORAGENICS INC received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Company reported stockholders equity of $3.2 million as of December 31, 2023, and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2023. The Notice further provides that

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-24-015404

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.